Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo, Jesse Meir Zaretsky, Lu Sun et al. · Cell · 2016
Cited by 3,432 works. doi:10.1016/j.cell.2016.02.065 Open-access PDF
Authors
- Willy Hugo
- Jesse Meir Zaretsky
- Lu Sun
- Blanca Homet Moreno
- Siwen Hu‐Lieskovan
- Beata Berent-Maoz
- Jia Pang
- Bartosz Chmielowski
- Grace Cherry
- Elizabeth Seja
- Shirley H. Lomeli
- Xiangju Kong
- Mark C. Kelley
- Jeffrey Alan Sosman
- Douglas Buckner Johnson
- Antoni Ribas
- Roger S. Lo
References
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
- TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
- Comprehensive molecular characterization of human colon and rectal cancer